Bonum Therapeutics

Three women and one man, wearing pink to show support for women leaders in biotech.

A group photo of 800-1,000 people wearing pink to show support for women leaders in biotech at the JPM Healthcare Conference in 2026.

With #JPM26 wrapped up, we’re proud to share a Bonum tradition: the #BiotechCEOSisterhood annual #WearPink photo. John Mulligan (@jtm42.bsky.social) & Diane Hollenbaugh joined returnees Cindy Lai Yee & Neela Patel, and hundreds of attendees, to celebrate #WomenInBiotech leadership & industry equity.

Connect with Bonum at #JPM26 next week!

• John Mulligan, Founder & CEO (@jtm42.bsky.social)
• Diane Hollenbaugh, Chief Scientific Officer
• Neela Patel, Chief Business Officer
• Cindy Yee, VP, Preclinical Development

Learn about our partnership interests: bonumtx.com/partnerships/

#JPMHealthcare

Illustration of a dual binding antibody

Bonum has secured a key U.S. patent protecting the unique mechanism of action behind our Dual-Binding Antibody (DBA) platform, covering marker-specific binding pairs such as LRRC15-IFNa, PD-L1-IFNa, PD1-IL2, and more.

Read more about this exciting milestone: www.businesswire.com/news/home/20...

Explore the next frontier in biologics at #BIO2025 with Bonum, Lumanity, Polaris Partners, @regeneron.com, Tentarix & Werewolf.

“Beyond Bispecifics & ADCs: Conditionally Active Biologics”
📍 Boston Convention & Exhibition Center, 206AB
🗓️ June 18 | 10:15–11:15 a.m. | 206AB

More: ow.ly/OBCa50W7aJO

A High-Potential Class of Next-Generation Biotherapies: Conditionally Active Biologics Ahead of BIO 2025, we’re sharing a short primer on a new class of next-generation biotherapies—conditionally active biologics—to set the stage for an informative panel discussion you won’t want to mis...

Want the most current insights on #CABs? Join us at #BIO2025 for the panel “Beyond ADCs and Bispecifics: Conditionally Active Biologics,” on Wed., June 18 from 10:15–11:15 a.m. ET.

Make sure to check out this short primer on the science behind CABs ahead of time: www.linkedin.com/pulse/high-p...

This #NationalCancerResearchMonth, Bonum joins the research community in honoring the scientists, clinicians, advocates & patients advancing cancer care. This year’s theme—#UnitedByCancerResearch: One Mission. One Voice.—is a powerful reminder that breakthroughs happen when we work together. #NCRM25

Chicago did not disappoint! Members of the Bonum team had a fantastic time at the #AACR25 Annual Meeting connecting with peers, partners, and pioneers in cancer research.

Thanks to @theaacr.bsky.social for bringing the global oncology community together in the Windy City.

#TargetedTherapeutics

A woman talking with a man at a conference table.

Startup life can be challenging, but for Cindy Yee, VP of Preclinical Development at @bonumtx.com, it’s been incredibly rewarding. Going from large orgs to a tight-knit team, she shares insights and lessons from the #biotech front lines for those eyeing a #startup. Check it out: ow.ly/b9JV50VstjN

Today, we proudly celebrate the 10th anniversary of the International Day of Women and Girls in Science! At Bonum Therapeutics, we recognize the critical role that women and girls play in science and technology each and every day. 🔬🧬

#WomenInScience #GirlsInStem #Steminist

A large group of women wearing items of pink clothing

Two women, wearing pink and waving at the camera

#FBF: Revisiting "In the Pink" at #JPM2025, a celebration of the contributions of women leaders in biotech & pharma—and their allies. Can you spot CBO Neela Patel & VP Cindy Yee in the #SeaOfPink?

Thanks to Biotech CEO Sisterhood, #Breaking7% & @cooleyllp.bsky.social for sponsoring! #ProjectMirror

The Bonum team will be on winter break from December 24 to January 1. We look forward to reconnecting in 2025. Wishing you and yours a safe and joyful holiday season!

Bonum's Linda Liang, Senior Dir. of Antibody Discovery, is featured in this month's Life Science Washington Executive Perspective! Learn how Linda & her team are discovering new molecules for therapeutics to revolutionize cancer treatment: lifesciencewajobs.com/2024/12/16/e...

#FindYourBestLifeinWA

Founder & CEO John Mulligan Shares Bonum Therapeutics'​ "No Jerks"​ Approach to Hiring As a serial biotech entrepreneur, I have spent a lot of time thinking about hiring, retaining and motivating people. The biotechnology industry depends heavily on highly skilled workers and the abilit...

Bonum Therapeutics is now on Bluesky! We're marking the occasion by revisiting insights from our founder & CEO, John Mulligan @jtm42.bsky.social, on his approach to hiring and retention: The 'No Jerks' Rule.

www.linkedin.com/pulse/founde...

#iykyk

Photo of Sam Blackman

We recently announced the appointment of Samuel Blackman, MD, PhD, to our board of directors as an independent director. His expertise & guidance will be instrumental in advancing Bonum's programs into the clinic.

Please join us in welcoming Sam to the Bonum team!

Full Release: ow.ly/I7yb50UjSSw

6 Tips For Successful Drug Discovery Teamwork <p>While people don&rsquo;t always think about the choreography of good scientific teamwork, there are factors that should be considered and skills that can be developed to increase a drug discovery team&rsquo;s overall effectiveness and chance of success.</p>

What makes a drug discovery team successful? Bonum’s Chief Scientific Officer, @Dianehollenba, offers up six tips for choreographing good scientific teamwork in the third installment of her series for Drug Discovery Online.

drugdiscoveryonline.com/doc/tips-for-s…

Bonum is proud to announce a $93M Series A financing to advance our conditionally active therapies. We're honored that all investors who backed our team at Good Therapeutics have continued their support, and we’ve welcomed a new investor to the syndicate:

ow.ly/OOqk50LEACt

The View from Business Development at Bonum Therapeutics By Neela Patel, Chief Business Development Officer I want to share my excitement about the launch of Bonum Therapeutics. It is a unique moment for the team at Bonum, all of whom joined from our predecessor company, Good Therapeutics – and the highlight to date of my career, both as a scientist and a

Chief Business Development Officer, Neela Patel, shares what’s next for Bonum’s validated technology platform.

ow.ly/qXkz50LjvFp

6 Drug Discovery Learnings From The Lab <p>With more than 25 years of experience, this author shares insights from the perspective of bench science that pertain to experimental design and data generation. These concepts apply not only to individual experiments but also more broadly.</p>

Diane Hollenbaugh (@Dianehollenba), Bonum’s Chief Scientific Officer, turns to experimental design and data generation in the second installment of her series for Drug Discovery Online.

ow.ly/TEQR50L2hlg

Welcome to the next chapter for the Good Therapeutics team -- introducing Bonum Therapeutics (@BonumTx)!

linkedin.com/pulse/welcome-…

We are excited to announce that @Roche has acquired Good Therapeutics’ innovative conditionally active PD-1-regulated-IL-2 program. The Good Therapeutics team has formed a new company, Bonum Therapeutics (@BonumTx). Learn more here:

ow.ly/QBxB50KC0ey